Medecision (MM) (MEDE) 뉴스

How about a the acceptance of a peer-reviewed manuscript titled, “Blarcamesine for the treatment of Early Alzheimer’s Disease: Results from the ANAVEX2-73-AD-004 Phase IIB/III trial,”

NEW YORK – November 25, 2024
Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasda

Marty,
Take a deep breath, think for a second, and don’t be so myopic.

If you are searching for hope for this company to succeed…..which one can assume that’s what your doing as you state, your a long, you need to take your “readers” off, take the blinders off, and really let

RGTI.....NVTS......https://stockcharts.com/h-sc/ui?s=NVTS&p=W&b=5&g=0&id=p84354014936

$DPUI tiny os history of making huge moves with a 600million OS this will run wild when volume comes in loading tickets here. 

So all the posters thinking a peer review would never happen are likely keeping a low profile today.

I don't see any name mentioned regarding the journal, expect: medical journal with focus on Alzheimer’s disease.

Further in the press release: “We are on track for regu

.58 flipping half from .47 

$VNTH another low floater dilution free shell insiders own many shares solid loading opportunities 

No.more shell risk on OTC 😍😍😍😍😍😍

QMCO....WLDS....MULN......................https://stockcharts.com/h-sc/ui?s=MULN&p=W&b=5&g=0&id=p84354014936

$PRDL nice dilution free shell insiders own 700mill shares keep on your radar.  

Simufilam did not meet endpoints: https://finance.yahoo.com/news/cassava-sciences-topline-phase-3-123000846.html

.53  style="caret-color: rgb(0, 0, 0); color: rgba(0, 0, 0, 1); font-family: -apple-system; font-size: 15px"“We now have evidence that the dramatic reduction of cognitive decline that was sustained over 6 months in patients treated with CT1812 who had lower plasma p-tau217 levels also was associated

$BWMG is the only profitable company that sells for .006!!!

Could this be a zip code changer!!! Do your own DD.

https://www.otcmarkets.com/filing/html?id=17989053&guid=F5Y-kqhAVXGaJth

The same IMMINENT news you posted 2-3 years ago. Please update us re which of those will occur between now and end of 2024. Thanks.

SAVA will be toast on open. Their cognitive improvement in Alzheimers is beaten by daily stretching and taking a walk in patients.
Atleast they canceled their other ph3 trial.... They have raised false hopes in too many patients already.
Question is will they face legal consequences fo

.47 . - Dramatic 95% Reduction of Cognitive Decline in CT1812-treated Patients with Lower Plasma p-tau217 Correlated with Improvements in Key Indicators of Alzheimer’s Disease Biology -

Goodbye Cassava

Doubt that is going to happen.... Hitting the 7s already this morning LOLOL>..

.56 pre market 

This is worth a repeat imho!!!!!!!!!!!!

Read earlier posts on RSS before you comment . There will be no RSS for 18-24 months. Only when we are ready and ""approved"" to uplist. There is no advantage for us over investors. When and if it happens it affects us as well.

tredenwater, OL trials are problematic in AD - we have seen that several times. I love the idea of a limited look and adjustment but not OL. I also really like Anavex's approach to trials - except for the size and number. FWIW, Anavex itself admits it screwed up - it was trying to do the bare min

https://www.prageru.com/video/dr-marty-makary-on-eye-opening-discoveries-in-health-and-medicine

New FDA COMMISSIONER SOON ENOUGH from JOHNS HOPKINS
help is arriving to clean out the skat
And the garbage finally

RDGL coming soon enough
MAYO CLINI

She'll risk removed on the otc profile!

Let's go!

“Blarcamesine for the treatment of Early Alzheimer’s Disease: Results from the ANAVEX2-73-AD-004 Phase IIB/III trial,” in a medical journal with focus on Alzheimer’s disease.

WTF, top tier I'm sure

$ILLR On alert!! Former Head of Product at TikTok Sean Kim joins Triller Group https://finance.yahoo.com/news/former-head-product-tiktok-sean-133000625.html